March 25,  2026 A Penn Medicine–led team has developed a first‑of‑its‑kind artificial intelligence system that interprets cardiac MRI scans with performance approaching expert clinicians. Trained on more than 300,000 MRI video clips from roughly 20,000 patients, the model can assess heart function and diagnose dozens of diseases using only non‑contrast imaging. The work was published in Nature Biomedical Engineering.

March 18, 2026  — UltraSight will present six clinical studies validating the performance of its UltraSight Echosystem at the 2026 American College of Cardiology’s Annual Scientific Session & Expo (ACC.26). The studies, conducted in collaboration with Mayo Clinic, confirm that the UltraSight Echosystem enables healthcare professionals without prior sonography training to acquire diagnostic-quality cardiac ultrasound images with greater than 95% accuracy across multiple patient populations and care settings.

March 25, 2026 — Royal Philips has launched its intuitive interventional guidance platform, IntraSight Plus, which is cleared for clinical use in the U.S. and Europe. With CE marking and FDA 510(k) clearance, the redesigned platform combines the most comprehensive diagnostic and treatment planning tools to deliver efficiency, simplicity and precision in a single intuitive system1.

March 24, 2026 — Physicians and investigators from the Smidt Heart Institute at Cedars-Sinai will present research and clinical insights during the American College of Cardiology’s Annual Scientific Session, March 28-30 in New Orleans.

Late-Breaking Science

March 24, 2026 — Physician-scientists from RWJBarnabas Health and Rutgers Health will present a dynamic portfolio of cardiovascular research at the American College of Cardiology's Annual Scientific Session & Expo (ACC.26), in New Orleans, LA, March 28–30, 2026. Seventy abstracts have been accepted, highlighting clinical insights and emerging science designed to advance prevention strategies, refine treatment approaches and improve outcomes for patients with cardiovascular disease.

March 24, 2026 — New research shows that small improvements to sleep, diet quality and physical activity, made in combination, are associated with a significantly reduced risk of major cardiovascular events such as stroke, heart attacks and heart failure.  

The study followed more than 53,000 adults from UK Biobank over an eight‑year period and found that making even modest improvements across three behaviors had clinically meaningful benefits.

March 24, 2026 — iPerf, a company specializing in the development of medical devices for cardiopulmonary support, has announced the first use of its new dual-flow femoral arterial cannula in a human patient. This transformative device integrates an additional flow to prevent the risk of limb ischemia in the cannulated leg, a major challenge in critical care and cardiac surgery, and features an innovative positioning system for percutaneous placement, ensuring greater precision for clinicians.

March 23, 2026  —Medtronic plc has received U.S. Food and Drug Administration (FDA) approval for an expanded indication for the OmniaSecure defibrillation lead.

Now approved for placement in the left bundle branch (LBB) area, the lead can be used for conduction system pacing (CSP), which closely mimics the heart's natural physiology. Additionally, patients in need of cardiac resynchronization may benefit from left bundle branch optimized cardiac resynchronization therapy (LOT-CRT), a novel therapy that combines CSP with left-ventricular pacing to further improve patient outcomes.

Controversies & Advances in the Treatment of Cardiovascular Disease

The Twenty-Fourth in the Series

37th Annual Cardiovascular Interventions

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now